These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30860438)

  • 41. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Tan PS; Aguiar P; Haaland B; Lopes G
    Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Updates on immunotherapy in non-small cell lung cancer.
    Shimanovsky A; Dasanu CA
    Expert Opin Biol Ther; 2014 Apr; 14(4):411-8. PubMed ID: 24512518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.
    Uprety D
    Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
    Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
    Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Lingering Questions in Immunotherapy.
    Wright K
    Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212135
    [No Abstract]   [Full Text] [Related]  

  • 47. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
    Waqar SN; Morgensztern D
    Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer.
    Davies M; Duffield E
    Clin J Oncol Nurs; 2020 Jun; 24(3):277-283. PubMed ID: 32441679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 50. Immunotherapy for non-small-cell lung cancer.
    Thomas A; Jakopovic M
    Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer.
    Stiles BM; Sepesi B; Broderick SR; Bott MJ
    J Thorac Cardiovasc Surg; 2020 Nov; 160(5):1376-1382. PubMed ID: 32763029
    [No Abstract]   [Full Text] [Related]  

  • 52. Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.
    Faehling M; Kopp M; Schwenk B; Fallscheer S; Kramberg S; Eckert R
    Oncology; 2019; 97(4):228-235. PubMed ID: 31216560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW; Chaft J; Hellmann M
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract]   [Full Text] [Related]  

  • 54. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
    Wanchoo R; Karam S; Uppal NN; Barta VS; Deray G; Devoe C; Launay-Vacher V; Jhaveri KD;
    Am J Nephrol; 2017; 45(2):160-169. PubMed ID: 28076863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].
    Berghmans T; Grigoriu B; Sculier JP; Meert AP
    Rev Mal Respir; 2018 Feb; 35(2):197-205. PubMed ID: 29395567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome].
    Shepherd FA; Douillard JY; Blumenschein GR
    Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):C9-20. PubMed ID: 23601304
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
    Chism DD
    J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 60. [Immunotherapy for lung cancer].
    Ostoros G
    Magy Onkol; 2017 Jun; 61(2):153-157. PubMed ID: 28585617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.